A controlled-release oral opioid supports S. aureus survival in injection drug preparation equipment and may increase bacteremia and endocarditis risk.
Autor: | Kasper KJ; Department of Microbiology and Immunology, Western University, London, Canada., Manoharan I; Department of Medicine, Western University, London, Canada., Hallam B; Department of Epidemiology and Biostatistics, Western University, London, Canada., Coleman CE; Department of Microbiology and Immunology, Western University, London, Canada., Koivu SL; Department of Family Medicine, Western University, London, Canada., Weir MA; Department of Medicine, Western University, London, Canada.; Lawson Health Research Institute, London, Canada., McCormick JK; Department of Microbiology and Immunology, Western University, London, Canada.; Lawson Health Research Institute, London, Canada., Silverman MS; Department of Microbiology and Immunology, Western University, London, Canada.; Department of Medicine, Western University, London, Canada.; Lawson Health Research Institute, London, Canada.; Division of Infectious Diseases, Western University, London, Canada. |
---|---|
Jazyk: | angličtina |
Zdroj: | PloS one [PLoS One] 2019 Aug 09; Vol. 14 (8), pp. e0219777. Date of Electronic Publication: 2019 Aug 09 (Print Publication: 2019). |
DOI: | 10.1371/journal.pone.0219777 |
Abstrakt: | Background: Injection drug use-associated endocarditis (IDUaIE) incidence in Ontario has recently been associated with hydromorphone prescribing rates. Staphylococcus aureus causes the majority of cases of IDUaIE in Ontario and across North America. Hydromorphone controlled-release (Hydromorphone-CR) requires a complex technique for injection and therefore provides multiple opportunities for contamination. Hydromorphone-CR contains several excipients, which could enhance staphylococcal survival and increase risk of contaminating the injectate. Methods: Used injection drug preparation equipment (cookers/filters) was collected from persons who inject drugs (PWID), rinsed with water, and plated on Mannitol salt agar. Bacterial isolates from bacteremic PWID were used to assess the survival of S. aureus and Streptococcus pyogenes on cookers/filters with Hydromorphone-CR, hydromorphone immediate-release (Hydromorphone-IR) or oxycodone controlled-release (Oxycodone-CR). The solutions spiked with S. aureus were heated and the remaining viable bacteria enumerated. Results: S. aureus was detected in 12/87 (14%, 95%CI 8-23%) cookers/filters samples used for injection of Hydromorphone-CR. Hydromorphone-CR was the only opioid associated with greater survival of methicillin-sensitive S. aureus (MSSA) and methicillin-resistant S. aureus (MRSA) on cookers/filters when compared to sterile water vehicle control. There was a ~2 log reduction in the number of S. aureus that survived when cookers/filters were heated. Conclusion: 14% of all cookers/filters used in the preparation of Hydromorphone-CR were contaminated with S. aureus. Hydromorphone-CR prolongs the survival of MRSA and MSSA in cookers/filters. Heating cookers/filters may be a harm-reduction strategy. Competing Interests: The authors have declared that no competing interests exist. |
Databáze: | MEDLINE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |